Lantern Pharma (NASDAQ: LTRN) reported fourth-quarter and full-year 2025 operational highlights led by continued progress in its LP-300 Phase 2 HARMONIC trial, completion of targeted enrollment in Japan, planned protocol discussions with the FDA in mid-May 2026 and advancement of LP-184, LP-284 and STAR-001 across multiple oncology indications. The company said its AI-driven portfolio now targets an estimated annual market opportunity of more than $15 billion, while its RADR(R) platform and newly introduced withZeta.ai multi-agentic co-scientist platform are expanding commercial potential, with beta testing underway at more than 25 biotech companies, cancer research centers and biopharma consultants, as Lantern ended 2025 with approximately $10.1 million in cash, cash equivalents and marketable securities.
To view the full press release, visit https://ibn.fm/nDpjO
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is an AI-driven biotechnology company focused on accelerating and optimizing the discovery, development, and commercialization of cancer therapies. Its proprietary RADR (R)platform leverages artificial intelligence and machine learning to uncover novel therapeutic opportunities, accelerate drug development timelines, and improve patient outcomes.
NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
